George L Sing Regeneron Pharmaceuticals, Inc. (REGN) insider trading activity

George L Sing is Director of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 27,828 shares of REGN, which is worth approximately $18.7 Million. The most recent transaction as insider was on Jan 02, 2025, when has been sold 166 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 27.8K

5.92% 3M change

5.61% 12M change

Total Value Held $18.7 Million

GEORGE L SING Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 02 2025	BUY Grant, award, or other acquisition	-	166 Added 0.59%	27,828 Common Stock
Dec 31 2024	SELL Payment of exercise price or tax liability	$1,379,554 $708.19 p/Share	1,948 Reduced 6.58%	27,662 Common Stock
Dec 31 2024	BUY Exercise of conversion of derivative security	$1,379,695 $413.33 p/Share	3,338 Added 10.13%	29,610 Common Stock
Sep 04 2024	SELL Bona fide gift	-	1,200 Reduced 4.37%	26,272 Common Stock
May 03 2024	SELL Payment of exercise price or tax liability	$826,598 $942.53 p/Share	877 Reduced 3.09%	27,472 Common Stock
May 03 2024	BUY Exercise of conversion of derivative security	$826,660 $413.33 p/Share	2,000 Added 6.59%	28,349 Common Stock
Feb 26 2024	SELL Open market or private sale	$992,500 $992.5 p/Share	1,000 Reduced 3.66%	26,349 Common Stock
Feb 26 2024	BUY Exercise of conversion of derivative security	$413,330 $413.33 p/Share	1,000 Added 3.59%	26,849 Common Stock
Feb 23 2024	SELL Open market or private sale	$492,500 $985.0 p/Share	500 Reduced 1.86%	26,349 Common Stock
Feb 23 2024	BUY Exercise of conversion of derivative security	$206,665 $413.33 p/Share	500 Added 1.83%	26,849 Common Stock
Feb 22 2024	SELL Open market or private sale	$2,895,000 $965.0 p/Share	3,000 Reduced 10.22%	26,349 Common Stock
Feb 22 2024	BUY Exercise of conversion of derivative security	$1,239,990 $413.33 p/Share	3,000 Added 9.89%	27,349 Common Stock
Feb 09 2024	SELL Open market or private sale	$477,500 $955.0 p/Share	500 Reduced 1.86%	26,349 Common Stock
Feb 09 2024	BUY Exercise of conversion of derivative security	$206,665 $413.33 p/Share	500 Added 1.83%	26,849 Common Stock
Feb 08 2024	SELL Open market or private sale	$472,500 $945.0 p/Share	500 Reduced 1.86%	26,349 Common Stock
Feb 08 2024	BUY Exercise of conversion of derivative security	$206,665 $413.33 p/Share	500 Added 1.83%	26,849 Common Stock
Jan 02 2024	BUY Grant, award, or other acquisition	-	135 Added 0.51%	26,349 Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	-	165 Added 0.63%	26,214 Common Stock
Feb 28 2022	SELL Open market or private sale	$1,231,000 $615.5 p/Share	2,000 Reduced 7.13%	26,049 Common Stock
Feb 25 2022	SELL Open market or private sale	$1,242,000 $621.0 p/Share	2,000 Reduced 6.66%	28,049 Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	191 Added 0.63%	30,049 Common Stock
Nov 22 2021	SELL Open market or private sale	$1,315,000 $657.5 p/Share	2,000 Reduced 6.28%	29,858 Common Stock
Nov 19 2021	SELL Open market or private sale	$655,000 $655.0 p/Share	1,000 Reduced 3.04%	31,858 Common Stock
Nov 18 2021	SELL Open market or private sale	$2,600,000 $650.0 p/Share	4,000 Reduced 10.85%	32,858 Common Stock
Nov 16 2021	SELL Open market or private sale	$3,937,560 $656.26 p/Share	6,000 Reduced 14.0%	36,858 Common Stock

GLS

George L Sing

Director

Tarrytown, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Value

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

Operation

Value

Type

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Track Activities on REGN

Account